Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Melior Discovery has signed an option agreement that provides Pfizer the exclusive right to negotiate a license to MLR-1023, Melior's drug candidate for type 2 diabetes.
Subscribe to our email newsletter
In exchange, Pfizer has agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior has agreed to utilize its in-vivo theraTRACE indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer.
Andrew Reaume, president and CEO of Melior, said: “This is the second collaboration initiated with Pfizer in the last 18 months and we look forward to this expansion to our productive R&D relationship.”